NICE recommends Angiox for STEMI
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued its final draft guidance recommending The Medicines Company's injectable anticoagulant Angiox (bivalirudin; Angiomax in the US) for ST-segment elevation myocardial infarction (STEMI) in patients undergoing primary percutaneous coronary intervention (PCI), when used in combination with aspirin and clopidogrel (Sanofi/Bristol-Myers Squibb's Plavix).